Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…

Paul Flynn Biography and Net Worth

EVP of DexCom

Paul Flynn is Executive Vice President, Global Revenue at Dexcom.

Paul assumed the role of Executive Vice President, Global Revenue in March 2021. In this role, he is responsible for global sales and commercial operations. Paul previously held various roles of Senior Vice President, General Manager Americas and Asia Pacific and Vice President, General Manager, Americas and Asia Pacific since joining Dexcom in 2015.

Prior to joining Dexcom, Paul served in numerous leadership capacities at Johnson & Johnson over the span of 23 years, including more than a decade in the diabetes space for both Lifescan and Animas Corporation. While at Johnson & Johnson, Paul established the Animas business in Canada and was also the Director, North American Sales for Animas Corporation.

Paul earned a Bachelor of Business Administration from Simon Fraser University and a Master of Business Administration from Wilfrid Laurier University.

What is Paul R. Flynn's net worth?: The estimated net worth of Paul R. Flynn is at least $3.94 million as of April 17th, 2023. Mr. Flynn owns 52,112 shares of DexCom stock worth more than $3,935,498 as of November 21st. This net worth estimate does not reflect any other investments that Mr. Flynn may own. Learn More about Paul R. Flynn's net worth.
How do I contact Paul R. Flynn?: The corporate mailing address for Mr. Flynn and other DexCom executives is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. DexCom can also be reached via phone at (858) 200-0200 and via email at [email protected]. Learn More on Paul R. Flynn's contact information.
Has Paul R. Flynn been buying or selling shares of DexCom?: Paul R. Flynn has not been actively trading shares of DexCom during the last ninety days. Learn More on Paul R. Flynn's trading history.
Who are DexCom's active insiders?: DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (CEO), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.
Are insiders buying or selling shares of DexCom?: During the last twelve months, insiders at the medical device company sold shares 28 times. They sold a total of 252,409 shares worth more than $33,128,636.21. The most recent insider tranaction occured on September, 9th when EVP Sadie Stern sold 426 shares worth more than $29,457.90. Insiders at DexCom own 0.3% of the company. Learn More about insider trades at DexCom.
Information on this page was last updated on 9/9/2024.

Paul R. Flynn Insider Trading History at DexCom

Paul R. Flynn Buying and Selling Activity at DexCom

DexCom Company Overview

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Today's Range

Now: $74.46

$74.14

$75.76

50 Day Range

MA: $70.43

$65.68

$76.27

2 Week Range

Now: $74.46

$62.34

$142.00

Volume

3,230,709 shs

Average Volume

3,924,849 shs

Market Capitalization

$29.08 billion

P/E Ratio

44.59

Dividend Yield

N/A

Beta

1.17

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

From Colonial Metals | Ad

Get Your Free Gold Guide